986 related articles for article (PubMed ID: 33670304)
21. Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19.
Al-Bari AA
Curr Drug Targets; 2020; 21(16):1703-1721. PubMed ID: 32552642
[TBL] [Abstract][Full Text] [Related]
22. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies.
Ortega JT; Zambrano JL; Jastrzebska B; Liprandi F; Rangel HR; Pujol FH
Intervirology; 2020; 63(1-6):2-9. PubMed ID: 33099545
[TBL] [Abstract][Full Text] [Related]
23. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Yao X; Ye F; Zhang M; Cui C; Huang B; Niu P; Liu X; Zhao L; Dong E; Song C; Zhan S; Lu R; Li H; Tan W; Liu D
Clin Infect Dis; 2020 Jul; 71(15):732-739. PubMed ID: 32150618
[TBL] [Abstract][Full Text] [Related]
24. Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?
Morris G; Athan E; Walder K; Bortolasci CC; O'Neil A; Marx W; Berk M; Carvalho AF; Maes M; Puri BK
Life Sci; 2020 Dec; 262():118541. PubMed ID: 33035581
[TBL] [Abstract][Full Text] [Related]
25. What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology.
Altulea D; Maassen S; Baranov MV; van den Bogaart G
J Mol Cell Biol; 2021 Jul; 13(3):175-184. PubMed ID: 33693723
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
[TBL] [Abstract][Full Text] [Related]
27. Chloroquine and its derivatives in the management of COVID-19: A scoping review.
Pimentel J; Andersson N
Biomedica; 2020 Oct; 40(Supl. 2):80-95. PubMed ID: 33152192
[TBL] [Abstract][Full Text] [Related]
28. Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective.
Perazzolo S; Zhu L; Lin W; Nguyen A; Ho RJY
J Pharm Sci; 2021 Mar; 110(3):1002-1017. PubMed ID: 33248057
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.
Plaze M; Attali D; Prot M; Petit AC; Blatzer M; Vinckier F; Levillayer L; Chiaravalli J; Perin-Dureau F; Cachia A; Friedlander G; Chrétien F; Simon-Loriere E; Gaillard R
Int J Antimicrob Agents; 2021 Mar; 57(3):106274. PubMed ID: 33387629
[TBL] [Abstract][Full Text] [Related]
30. Coronavirus Infection-Associated Cell Death Signaling and Potential Therapeutic Targets.
Yapasert R; Khaw-On P; Banjerdpongchai R
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946543
[TBL] [Abstract][Full Text] [Related]
31.
Khan FI; Hassan F; Lai D
Front Immunol; 2021; 12():794780. PubMed ID: 35095870
[TBL] [Abstract][Full Text] [Related]
32. COVID-19: Potential Repurposing Drugs.
Leowattana W
Infect Disord Drug Targets; 2022; 22(1):e110122191924. PubMed ID: 33645490
[TBL] [Abstract][Full Text] [Related]
33. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.
Shawki MA; Elsayed NS; Mantawy EM; Said RS
Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):395-409. PubMed ID: 34057871
[TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions.
Asrani P; Hassan MI
Mol Cell Biochem; 2021 Feb; 476(2):675-687. PubMed ID: 33064288
[TBL] [Abstract][Full Text] [Related]
35. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.
Homolak J; Kodvanj I
Int J Antimicrob Agents; 2020 Aug; 56(2):106044. PubMed ID: 32522674
[TBL] [Abstract][Full Text] [Related]
36. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
[TBL] [Abstract][Full Text] [Related]
37. Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2.
Su H; Zhou F; Huang Z; Ma X; Natarajan K; Zhang M; Huang Y; Su H
Angew Chem Int Ed Engl; 2021 Apr; 60(18):9789-9802. PubMed ID: 32729180
[TBL] [Abstract][Full Text] [Related]
38. Effects of sEH inhibition on the eicosanoid and cytokine storms in SARS-CoV-2-infected mice.
Edin ML; Gruzdev A; Graves JP; Lih FB; Morisseau C; Ward JM; Hammock BD; Bosio CM; Zeldin DC
FASEB J; 2024 May; 38(10):e23692. PubMed ID: 38786655
[TBL] [Abstract][Full Text] [Related]
39. Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies.
Han N; Hwang W; Tzelepis K; Schmerer P; Yankova E; MacMahon M; Lei W; M Katritsis N; Liu A; Felgenhauer U; Schuldt A; Harris R; Chapman K; McCaughan F; Weber F; Kouzarides T
Sci Adv; 2021 Jun; 7(27):. PubMed ID: 34193418
[TBL] [Abstract][Full Text] [Related]
40. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
Solimani F; Meier K; Ghoreschi K
Eur J Immunol; 2021 May; 51(5):1071-1075. PubMed ID: 33675065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
